$14.32
2.29%
Nasdaq, Apr 21, 07:37 pm CET
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Pharvaris NV Stock price

$14.00
-2.50 15.15% 1M
-7.25 34.12% 6M
-5.17 26.97% YTD
-7.20 33.96% 1Y
-3.61 20.50% 3Y
-6.00 30.00% 5Y
-6.00 30.00% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.28 2.04%
ISIN
NL00150005Y4
Symbol
PHVS
Sector
Industry

Key metrics

Market capitalization $762.90m
Enterprise Value $473.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.75
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-157.48m
Free Cash Flow (TTM) Free Cash Flow $-128.72m
Cash position $290.69m
EPS (TTM) EPS $-2.69
P/E forward negative
Short interest 1.42%
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Pharvaris NV forecast:

7x Buy
88%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Sell
13%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.29 0.29
4% 4%
-
-0.29 -0.29
4% 4%
-
- Selling and Administrative Expenses 50 50
51% 51%
-
- Research and Development Expense 107 107
50% 50%
-
-157 -157
50% 50%
-
- Depreciation and Amortization 0.29 0.29
4% 4%
-
EBIT (Operating Income) EBIT -157 -157
50% 50%
-
Net Profit -145 -145
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
GlobeNewsWire
14 days ago
ZUG, Switzerland, April 07, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for t...
Neutral
GlobeNewsWire
20 days ago
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commi...
Neutral
GlobeNewsWire
about 2 months ago
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of...
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 108
Founded 2015
Website www.pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today